Hvis behandling med Stalevo (levodopa/ carbidopa/ entakapon) afbrydes, og patienten overføres til behandling med levodopa/ DDC- hæmmer uden entakapon, er det nødvendigt at justere doseringen af anden antiparkinson- behandling, specielt levodopa, for at opnå tilstrækkelig kontrol over parkinsonsymptomerne.
If Stalevo treatment (levodopa/ carbidopa/ entacapone) is discontinued and the patient is transferred to levodopa/ DDC inhibitor therapy without entacapone, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms.